secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-109241
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mallinckrodt completes spin-off of Par Health, renames as Keenova Therapeutics
------------------------------------------------------------------------------

- Spin-off of Par Health (generic pharma and sterile injectables) completed Nov 10, 2025; Mallinckrodt renamed to Keenova Therapeutics.
- Par Health becomes an independent private company; no longer listed on any exchange.
- CVR agreement with Opioid Master Disbursement Trust II terminated for $35M payment.
- Keenova intends to list on NYSE in 2026 with a public offering; 2024 pro-forma revenue $1.7B, >1,600 employees.
- Leading products: Acthar Gel and XIAFLEX; focus on rare/unaddressed conditions across multiple therapeutic areas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000110465925109241/0001104659-25-109241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000110465925109241/tm2530694d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer